Markets:

Overview

News

Currencies

International

Treasuries

SCYNEXIS, Inc. - Common Stock (NQ:SCYX)

1.075 +0.055 (+5.40%)

Streaming Delayed Price Updated: 9:56 AM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SCYNEXIS, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 ↗

March 01, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

February 06, 2023

We're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday!

Via InvestorPlace

SCYNEXIS's Return On Capital Employed Overview ↗

December 13, 2022

Via Benzinga

Scynexis Looks For Commercial Partner For Its Lead Infection Treatment ↗

October 20, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

December 30, 2022

Friday's session saw 75 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

December 28, 2022

On Wednesday, 258 companies hit new 52-week lows.

Via Benzinga

Scynexis Touts Postive Data For Ibrexafungerp For Vaginal Infections ↗

July 19, 2022

Via Benzinga

SCYNEXIS: Q1 Earnings Insights ↗

May 12, 2022

SCYNEXIS (NASDAQ:SCYX) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections ↗

April 22, 2022

Via Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Looking Into SCYNEXIS's Return On Capital Employed ↗

September 09, 2022

Benzinga Pro data, SCYNEXIS (NASDAQ:SCYX) reported Q2 sales of $1.32 million. Earnings fell to a loss of $13.35 million, resulting in a 144.82% decrease from last quarter.

Via Benzinga

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗

September 08, 2022

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Earnings Scheduled For August 15, 2022 ↗

August 15, 2022

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.

Via Benzinga

SCYNEXIS Shares Climb As FDA Accepts Filing For Vaginal Yeast Infection Candidate Under Priority Review ↗

August 01, 2022

SCYNEXIS (NASDAQ: SCYX) announced that the U.S. Food and Drug Administration (FDA) has accepted its submission of a supplemental New Drug Application (sNDA) to expand the label of BREXAFEMME...

Via Benzinga

Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday ↗

July 21, 2022

Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.

Via Benzinga

This Communication Services Stock Is Trading Higher By Over 82%, Here Are 45 Stocks Moving In Wednesday's Mid-Day Session ↗

July 20, 2022

Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 82.2% to $2.6787. Direct Digital Holdings said its supply-side advertising platform, Colossus SSP, reported a 540% year-over-year...

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary ↗

July 19, 2022

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 16, 2022

Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $258.9 million.

Via Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗

May 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Outlook For SCYNEXIS ↗

May 11, 2022

SCYNEXIS (NASDAQ:SCYX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that SCYNEXIS will...

Via Benzinga

Mid-Afternoon Market Update: Dow Dips Over 800 Points; HCA Healthcare Shares Plunge ↗

April 22, 2022

U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping more than 800 points on Friday.

Via Benzinga

Earnings Scheduled For May 12, 2022 ↗

May 12, 2022

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.

Via Benzinga

55 Biggest Movers From Friday ↗

April 25, 2022

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate...

Via Benzinga

Mid-Day Market Update: Nasdaq Down 200 Points; Blueknight Shares Spike Higher ↗

April 22, 2022

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 200 points on Friday.

Via Benzinga

Mid-Morning Market Update: Markets Open Lower; Dow Tumbles 400 Points ↗

April 22, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 400 points on Friday.

Via Benzinga

The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial ↗

April 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 22, 2022

Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 94.7% to $2.2 during Friday's pre-market session. The company's market cap stands at $14.9 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

April 22, 2022

Traders ready for another busy day of investing will want to know all about the biggest pre-market stock movers for Friday!

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.